# Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)

> **NCT03449173** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 56 (estimated)

## Conditions studied

- Type B3 Thymoma
- Thymic Carcinoma

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03449173
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-02
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449173, "Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03449173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*